SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2018
ACADIA Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
3611 Valley Centre Drive, Suite 300
San Diego, California
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 558-2871
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) At the recommendation of Stephen R. Davis, the Chief Executive Officer (CEO) of ACADIA Pharmaceuticals Inc. (the Company), the Board of Directors of the Company approved the promotion, effective November 19, 2018 (the Effective Date), of Srdjan R. Stankovic, M.D., M.S.P.H., the Companys Executive Vice President and Head of Research and Development, to the position of President. Dr. Stankovic will continue to report to Mr. Davis, ACADIAs CEO. Dr. Stankovic will continue to lead ACADIAs research and development efforts. Dr. Stankovics biographical and compensation information, as well as descriptions of the Companys agreements and arrangements with Dr. Stankovic, are available in the Companys Definitive Proxy Statement filed April 30, 2018, and are incorporated herein by reference.
On the Effective Date, Dr. Stankovics base salary and target bonus percentage were increased to $675,000 and to 65%, respectively. In addition, Dr. Stankovic was granted an option to purchase up to 150,000 shares of the Companys common stock, having an exercise price of $18.12 per share (the closing price of the Companys common stock as reported on the Nasdaq Global Select Market on the Effective Date), and 25,000 restricted stock units.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 20, 2018||ACADIA Pharmaceuticals Inc.|
|By: /s/ Austin D. Kim|
|Name:||Austin D. Kim|
|Title:||Executive Vice President, General Counsel &|